|
|
BIO:ON Insight EN #1 ยท Jun 7, 2026 ยท AI Vaccine Design ยท KRAS ยท Gene Editing Three "impossible" problems, one week.
|
|
Putting this week's stories side by side, one word kept coming up: impossible. AI couldn't design a vaccine. KRAS couldn't be drugged, and people had been saying that for thirty years. Gene editing was always a few years away. This week all three of those claims took a hit. A Cambridge vaccine designed by AI cleared a human trial, daraxonrasib doubled survival in pancreatic cancer, and CRISPR Therapeutics kept turning gene editing into real medicines. Here's what each one means if you're trying to build a career in this industry.
โ Editor ยท MSc Biotechnology & Pharmaceutical Management
|
๐ค Word of the Week
Gene Editing Pipeline
The idea behind this week's CRISPR Therapeutics story (Story 3)
Gene editing uses tools like CRISPR-Cas9 to cut and correct DNA inside a cell with high precision. A pipeline is a company's line-up of drug candidates, queued from preclinical through Phase 1, 2 and 3 to approval. Put together, a gene editing pipeline is a roadmap of how close each gene-edited treatment is to patients. CRISPR Therapeutics already has one approval, the sickle cell treatment Casgevy, and is now pushing into cardiovascular disease and blood cancers.
Ex vivo โ edit the cells outside the body
Blood cells are taken out, edited with CRISPR, then infused back. This is how Casgevy works. Manufacturing is complex and expensive, but the editing is very precise.
In vivo โ edit inside the body
The editing tool is delivered straight into the body and changes DNA in the target cells where they are. Next-generation programmes like CTX310 (ANGPTL3, cardiovascular) aim here. Simpler for patients, but delivery and safety are the hard part.
๐ฐ This Week's Top 3 Stories
Cambridge's AI-Designed Vaccine Becomes the First to Clear a Human Trial
University of Cambridge / Crypto Briefing | Jun 2026
Key Facts
A University of Cambridge team reported that a vaccine designed from scratch by AI passed a Phase 1 human trial. It's being called a world first because the AI didn't just check candidates proposed by researchers: it led the design of the antigen itself. Trained on large immunology datasets, the model predicted and designed an antigen structure to optimise the immune response, and the result showed safety and immunogenicity in people.
Plain-English Breakdown ๐งฉ
Traditional vaccine work means screening thousands of candidate antigens by trial and error until one triggers a good immune response. AI swaps that for prediction and designs a candidate that should work from the start. It's like writing a hit song instead of sifting through thousands of songs to find one. A Phase 1 pass means "safe, and it triggers an immune response" โ efficacy still needs more trials. But an AI-led biological design working in humans is a milestone on its own.
๐ Global Lens
The UK has been selling itself as a home for both life sciences and AI, and a Cambridge result like this strengthens that pitch to investors and pharma partners. The harder question is for regulators: the MHRA, FDA and EMA have all published papers or draft guidance on AI in medicines development, and a vaccine whose antigen came from a model is exactly the kind of case that will test it.
Why it matters for your career: There's a lot of hype around AI drug discovery. Hiring managers remember the candidate who can tell a first-in-human milestone apart from proof that a drug works.
๐ The first AI-designed vaccine antigen to show safety and immunogenicity in a Phase 1 human trial. โ University of Cambridge / Crypto Briefing summary
Revolution Medicines' daraxonrasib Doubles Pancreatic Cancer Survival in Phase 3
ScienceAlert / Revolution Medicines (Nasdaq: RVMD) | Phase 3 ยท 500 patients
Key Facts
In a 500-patient Phase 3 trial in metastatic pancreatic cancer, daraxonrasib raised overall survival from 6.7 to 13.2 months versus standard care and cut the risk of death by 60%. More than 90% of pancreatic cancers are driven by KRAS mutations, and KRAS has been considered "undruggable" for 30 years. Instead of binding KRAS directly, daraxonrasib recruits a helper protein, cyclophilin A, to lock onto KRAS indirectly. The main side effect was rash (86% of patients), yet quality of life was better than on chemotherapy.
Plain-English Breakdown ๐งฉ
KRAS is often compared to a smooth ball with nothing to grab onto: no pocket for a drug to sit in, which is why people gave up on it for decades. daraxonrasib doesn't try to grab the ball. It grabs the hand that throws it (cyclophilin A) so the ball never gets thrown. Doubling survival matters even more here because pancreatic cancer has a five-year survival rate of only about 12%, with very few treatment options.
๐ Global Lens
Pancreatic cancer is one of the deadliest cancers worldwide, so doubling survival matters far beyond the US. Outside America, though, the real question is access. In the UK, NICE will weigh the survival gain against the price, and each European payer runs its own version of that sum, so patients in different countries could get this drug years apart.
Why it matters for your career: Quoting the endpoint, the effect size and the main safety signal in one go is exactly what clinical and medical roles test for.
๐ Overall survival 6.7 โ 13.2 months and a 60% lower risk of death in metastatic pancreatic cancer, via indirect KRAS inhibition through cyclophilin A. โ ScienceAlert / Revolution Medicines summary
CRISPR Therapeutics Moves Beyond Casgevy Into Heart Disease and Blood Cancer
Yahoo analysis / CRISPR Therapeutics (Nasdaq: CRSP) | Pipeline update
Key Facts
An analysis argued that CRISPR Therapeutics, despite heavy short interest, could see its pipeline re-rated. After Casgevy (exa-cel), co-developed with Vertex and approved in 2023 for sickle cell disease and beta thalassaemia, the company is developing CTX310 (ANGPTL3) and CTX320 (Lp(a)) in cardiovascular disease, plus CTX112, an allogeneic CAR-T for blood cancers. A one-time treatment that permanently corrects a genetic error is a fundamentally different value proposition from a daily pill.
Plain-English Breakdown ๐งฉ
Most drugs manage symptoms every day for life. A CRISPR treatment aims to fix the DNA error once and remove the cause. Casgevy edits the DNA of a sickle cell patient's blood cells directly, with results close to a cure. Heavy short interest means the market still sees a lot of uncertainty, while a possible re-rating is the view that today's price may undervalue what's in the pipeline. The Word of the Week above shows how the pipeline fits together.
๐ Global Lens
Casgevy's rollout shows how differently health systems handle a one-time cure. The UK's MHRA was the first regulator in the world to approve it, in late 2023, and NHS England has since agreed deals to fund it, while US access runs through insurers and outcomes-based agreements. Heart disease affects millions, so whoever works out how to pay for a one-off treatment will shape that market everywhere.
Why it matters for your career: Gene therapy companies need people who understand manufacturing and reimbursement as well as the biology, which opens real doors for candidates who don't want to stay at the bench.
๐ A solid pipeline after Casgevy: CTX310 and CTX320 in cardiovascular disease and CTX112 in blood cancer. Short interest is high, but a re-rating is on the table. โ Yahoo analysis summary
๐ฌ This Week's Deep Dive
|
||||||||||||||||||||||||||||||||||
๐ก Editor's Insight
๐ Numbers of the Week
|
1st |
AI-designed vaccine to clear a human trial University of Cambridge: the first vaccine with an AI-led antigen design to pass Phase 1. |
|
2ร |
Pancreatic cancer survival (6.7 โ 13.2 months) daraxonrasib Phase 3, with a 60% lower risk of death. A 30-year "undruggable" target, finally hit. (Revolution Medicines) |
|
3+ |
CRISPR Therapeutics clinical programmes After Casgevy: CTX310 and CTX320 (cardiovascular) and CTX112 (blood cancer). (CRSP) |
๐ 3 Stocks That Moved This Week
Direction and catalyst, sketched โ not exact prices. Check a real chart for that.
|
Revolution Medicines NASDAQ: RVMD |
|
โฒ Strong |
Shares rose sharply after the Phase 3 readout. Specific numbers (survival doubled, 60% lower risk of death) gave the market something concrete to price, and an FDA filing now looks close. Hiring signal: a company heading toward its first launch usually starts building Medical Affairs, Market Access and commercial teams. (Directional sketch.)
|
CRISPR Therapeutics NASDAQ: CRSP |
|
โ Mixed |
High short interest kept things volatile, but talk of a pipeline re-rating brought in dip buyers. Upcoming data from CTX310 and CTX112 could be the trigger for a re-rating. Hiring signal: in vivo cardiovascular programmes lean heavily on delivery and CMC expertise. (Directional sketch.)
|
Vertex Pharmaceuticals NASDAQ: VRTX |
|
โฒ Edging up |
As Casgevy's co-developer, Vertex picked up some of the attention on gene editing, and its cystic fibrosis franchise (vanzacaftor and others) keeps it positioned as the steadier large-cap. (Directional sketch.)
๐ Why this pattern
RVMD moved most because it had hard data: "survival doubled" is a signal the market can price immediately. CRSP has pipeline value but no fresh data, and short pressure made it choppy. VRTX, as a large cap, barely moved. Same "good biotech news" week, very different reactions depending on how concrete the data was and what kind of stock it hit. (All directional sketches โ check a real chart for exact prices.)
๐ฏ Roles to Watch This Week
Teams worth watching based on this issue's news โ not live job postings, so check each company's careers page for what's actually open.
|
Revolution Medicines โ Medical Affairs / Clinical Development Why now: with a Phase 3 win in hand and a filing ahead, the company will need people to prepare regulatory submissions, run follow-on trials in other KRAS-driven cancers, and brief oncologists. Look under "Medical Affairs" or "Clinical Development." |
|
CRISPR Therapeutics โ CMC / Delivery Science Why now: moving from ex vivo editing (Casgevy) to in vivo cardiovascular programmes shifts the challenge toward delivery and manufacturing. Look under "CMC," "Process Development" or "Delivery." |
|
AI-driven vaccine groups โ Computational Biology Why now: an AI-designed antigen working in humans will pull more vaccine programmes toward in silico design. Look for "Computational Biology" or "Immunoinformatics" roles at vaccine companies and university spin-outs. |
๐๏ธ Dates to Watch
| When / Event | Why It Matters |
|---|---|
|
H2 2026 (expected) Revolution Medicines โ daraxonrasib FDA filing |
A filing based on the Phase 3 win. If approved, it would be the first KRAS-targeted treatment for pancreatic cancer. |
|
Autumn 2026 (expected) ESMO Congress 2026 โ pancreatic cancer and KRAS data |
Where competing KRAS inhibitors and follow-on indications are likely to show up after daraxonrasib. |
|
Ongoing CRISPR Therapeutics CTX310 / CTX112 Phase 1/2 ยท Cambridge AI vaccine follow-up trials |
Early efficacy signals for CTX310 and whether the AI vaccine moves into Phase 2 are the next things to watch. |
How was this issue?
| ๐ Loved it ๐ค Could be better |
|
Found this useful? Share it with a classmate. ๐ค Share the subscribe linkFollow along โ @bio.on_insight |
Global biotech & pharma news, translated into career signal โ ๐ Read on the web ยท past issues archive โ bioon-website.vercel.app ยฉ 2026 BIO:ON Insight ยท Unsubscribe here. |